| 1 |
Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-12.
DOI
|
| 2 |
Qi WX, He AN, Tang LN, Shen Z, Lin F, Yao Y. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol 2012;42:427-31.
DOI
|
| 3 |
Pawinski A, Crowther D, Keizer HJ, Voute PA, Somers R, van Glabbeke M, et al. The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma. Eur J Cancer 1999;35:163-4.
DOI
|
| 4 |
Song BS, Seo J, Kim DH, Lim JS, Yoo JY, Lee JA. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr Blood Cancer 2014;61:1376-81.
DOI
|
| 5 |
Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/ refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 2009;31:723-9.
DOI
|
| 6 |
Nitschke R, Pratt C, Harris M, Krischer J, Vietti TJ, Grier H, et al. Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A phase II study (Pediatric Oncology Group). Invest New Drugs 1992;10:93-6.
DOI
|
| 7 |
Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011;17:611-9.
DOI
|
| 8 |
Ministry for Health, Welfare and Family Affairs. Annual report of cancer incidence (2011), cancer prevalence (2011) and survival (1993-2011) in Korea. Seoul: Ministry for Health, Welfare and Family Affairs, 2011.
|
| 9 |
Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009;152:239-62.
DOI
|
| 10 |
Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, et al. Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients. Klin Padiatr 1999;211:260-70.
DOI
|
| 11 |
Lee JA, Park BK; for the Korean Society of Pediatric Hematology and Oncology. Osteosarcoma of children and adolescents: analysis from the Korean Society of Pediatric Hematology-Oncology (KSPHO). In: Proceedings of the 59th Annual Meeting of the Korean Pediatric Society; 2009 Oct 23-24; Seoul, Korea.
|
| 12 |
Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, et al. Long-term results of the co-operative German-Austrian- Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893-9.
DOI
|
| 13 |
Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003;21:710-5.
DOI
|
| 14 |
Lee YJ, Lee HJ, Kim DH, Lim JS, Lee JH, Park KD, et al. Outcome after relapse in childhood and adolescent osteosarcoma: single institution experience in Korea. Korean J Pediatr 2008;51:78-83.
DOI
|
| 15 |
Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-31.
DOI
|
| 16 |
Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno- Neumann S, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006;119:706-11.
DOI
|
| 17 |
McGovern SL, Mahajan A. Progress in radiotherapy for pediatric sarcomas. Curr Oncol Rep 2012;14:320-6.
DOI
|
| 18 |
Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007;25:2755-63.
DOI
|
| 19 |
Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-25.
DOI
|
| 20 |
Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer 2012;59:854-8.
DOI
|
| 21 |
Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S. The role of radiotherapy in oseosarcoma. Cancer Treat Res 2009;152:147-64.
DOI
|
| 22 |
Oertel S, Blattmann C, Rieken S, Jensen A, Combs SE, Huber PE, et al. Radiotherapy in the treatment of primary osteosarcoma: a single center experience. Tumori 2010;96:582-8.
DOI
|
| 23 |
DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005;61:492-8.
DOI
|
| 24 |
Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006;16:2-9.
DOI
|
| 25 |
Anderson P, Aguilera D, Pearson M, Woo S. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control 2008;15:38-46.
DOI
|
| 26 |
Lee JA, Song BS, Choi AR, Lim SW, Ahn JH, Seo JH, et al. Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma. In: Proceedings of the 63th Annual Meeting of the Korean Pediatric Society; 2013 Oct 18-19; Seoul, Korea.
|
| 27 |
Salama JK, Vokes EE. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol 2013;31:1029-38.
DOI
|
| 28 |
Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:189-96.
DOI
|
| 29 |
Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153- EDTMP and radium-223. Adv Exp Med Biol 2014;804:291-304.
DOI
|
| 30 |
Kebudi R, Gorgun O, Ayan I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr Blood Cancer 2004;42:320-4.
DOI
|
| 31 |
Saleh RA, Graham-Pole J, Cassano W, Abbot F, Vander Griend R, Dickson N, et al. Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer 1990;65:861-5.
DOI
|
| 32 |
Rodriguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002;24:250-5.
DOI
|
| 33 |
Srinivasan U, Reaman GH, Poplack DG, Glaubiger DL, LeVine AS. Phase II study of 5-azacytidine in sarcomas of bone. Am J Clin Oncol 1982;5:411-5.
DOI
|
| 34 |
Pratt CB, Meyer WH, Howlett N, Douglass EC, Bowman LC, Poe D, et al. Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Cancer 1994;74:2593-8.
DOI
|
| 35 |
Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 2004;16:120-5.
DOI
|
| 36 |
Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832-35.
DOI
|
| 37 |
Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res 1998;4:357-60.
|
| 38 |
Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A, Vassallo E, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002;20:2150-6.
DOI
|
| 39 |
Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009;115:5339-48.
DOI
|
| 40 |
Meyers PA, Chou AJ. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv Exp Med Biol 2014;804:307-21.
DOI
|
| 41 |
Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, et al. Insulin- like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS One 2014;9:e106249.
DOI
|
| 42 |
Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 2015;16:98-107.
DOI
|
webmaster
